Standout Papers

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with ad... 2009 2026 2014 2020 570
  1. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial (2009)
    Yoon‐Koo Kang, Won Ki Kang et al. Annals of Oncology

Immediate Impact

2 from Science/Nature 103 standout
Sub-graph 1 of 18

Citing Papers

Oesophageal cancer
2024 Standout
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
2023 Standout
2 intermediate papers

Works of D.B. Shin being referenced

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
2015
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
2009 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
D.B. Shin 390 591 263 266 17 685
Dmitry Bichev 312 611 340 238 15 660
M. Wenczl 416 548 197 114 15 690
V. Mutri 422 416 187 117 22 610
Nadine Röthling 310 486 397 81 11 645
Alberto Di Leo 108 545 285 273 16 629
G Mori 113 508 349 235 12 585
Sunao Moriguchi 151 434 326 133 17 635
Junichiro Nasu 342 586 301 324 26 768
S. Giaquinta 477 455 214 117 24 658
Pamela Dumas 245 503 254 243 13 670

All Works

Loading papers...

Rankless by CCL
2026